



ORIGINAL RESEARCH ARTICLE

A cohort study of 49 933 women with surgically verified endometriosis: Increased incidence of breast cancer below the age of 40

Liisu Saavalainen¹  | Heini Lassus¹ | Anna But² | Aila Tiitinen¹ | Päivi Härkki¹ | Mika Gissler^{3,4} | Eero Pukkala^{5,6} | Oskari Heikinheimo¹ 

¹Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

²Biostatistics Consulting, Department of Public Health, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

³National Institute for Health and Welfare (THL), Helsinki, Finland

⁴Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

⁵Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland

⁶Faculty of Social Sciences, University of Tampere, Tampere, Finland

Correspondence

Oskari Heikinheimo, Department of Obstetrics and Gynecology, Helsinki University Hospital, PO Box 140, FI-00029 HUS, Helsinki, Finland.
Email: oskari.heikinheimo@helsinki.fi

Funding information

This study has been funded by the Hospital District of Helsinki and Uusimaa, and by the Finnish Medical Research Foundation.

ABSTRACT

Introduction: The association between endometriosis and breast cancer is unclear. We assessed the risk of breast cancer in women with surgically verified endometriosis, with special focus on the age at cancer diagnosis, time from endometriosis diagnosis and breast cancer histology.

Material and methods: All women with first endometriosis-associated diagnoses occurring concomitantly with relevant surgical codes during 1987-2012 were retrieved from the Finnish Hospital Discharge Register in Finland. Breast cancers diagnosed after the endometriosis diagnosis were identified from the Finnish Cancer Registry. The Finnish female population served as the reference. The endometriosis cohort consisted of 49 933 women (23 210 cases of ovarian, 20 187 peritoneal and 2372 deep infiltrating endometriosis). The outcome measure was the standardized incidence ratio (SIR) with 95% confidence interval (95% CI) of breast cancer calculated for the whole cohort and for the subtypes of endometriosis, stratified by the age at breast cancer diagnosis, histology and time from endometriosis diagnosis.

Results: The overall risk of breast cancer (1555 cases) was similar to the reference population (SIR 0.99; 95% CI 0.94-1.03), did not differ in types of endometriosis, and was similar for ductal and lobular breast cancer. However, the SIR of breast cancer was increased in the age group of 20-29 years (SIR 4.44; 95% CI 2.22-7.94) and in the age group of 30-39 years (SIR 1.28; 95% CI 1.03-1.57). The risk of in situ breast cancer (170 cases) was increased in the entire endometriosis cohort (SIR 1.25; 95% CI 1.07-1.44).

Conclusions: The overall risk of breast cancer in women with surgically verified endometriosis was similar to that of general population. However, the risk of breast cancer at young age was increased. Young women with surgically verified endometriosis represent highly symptomatic patients with more frequent surgeries and additional therapies that might also contribute to the risk of breast cancer.

KEYWORDS

breast cancer, deep infiltrating endometriosis, endometriosis, ovarian endometriosis, peritoneal endometriosis

1 | INTRODUCTION

Endometriosis is a chronic inflammatory disease of the female pelvis affecting 6%-10% of fertile-age women, resulting in increased morbidity including pelvic pain and subfertility.¹ The risk factors relate to increased exposure to menstruation, such as early menarche, short menstrual cycle length and longer menstrual duration, as well as reduced parity.¹ The etiology is uncertain, but it includes genetic, environmental and immunological abnormalities.² A key feature of ectopic endometriotic implants is their capacity for autonomic estrogen production.³ In clinical practice, endometriosis is divided into three different subgroups: ovarian, peritoneal and deep infiltrating endometriosis. The pathogenesis of these entities might differ.⁴

Breast cancer is the most common cancer and cause of cancer death in women worldwide.⁵ General risk factors include genetic factors, reproductive, hormonal and life-style related factors such as nulliparity, early menarche or late menopause, current or recent use of oral contraceptives or combined menopausal hormone therapy, obesity, physical inactivity and excess alcohol consumption.⁶

Previous studies assessing the relation between endometriosis and breast cancer have reported conflicting results. Some recent large studies have suggested that the risk of breast cancer among endometriosis patients is increased,⁷⁻⁹ whereas several other studies report no such risk.¹⁰⁻¹⁵ A cross-sectional study from North America found a decreased prevalence.¹⁶

We have previously assessed the risk of gynecological and non-gynecological cancers according to the type of endometriosis.^{17,18} We found that the overall risk of breast cancer in women with surgically verified endometriosis was similar to that of the Finnish female population.¹⁷ Moreover, the risk did not differ according to the type of endometriosis. However, as breast cancer is the most common cancer among fertile women and a concern to all women, we further explored the risk of breast cancer according to age at breast cancer diagnosis, time from endometriosis diagnosis as well as breast cancer histology (ie, ductal and lobular) and separately for breast carcinoma in situ.

2 | MATERIAL AND METHODS

In this historic register-based cohort study, all first diagnoses of endometriosis, either main or subsidiary, were identified from the Finnish Hospital Discharge Registry when existing concomitantly with a relevant procedural code for the first time from 1987 to 2012. The Finnish Hospital Discharge Registry has national coverage and includes personal identity codes, codes for diseases according to the International Classification of Diseases (ICD), procedure codes according to the Nordic Medico-Statistical Committee Classification of Surgical Procedures (NCSP) and dates for each hospital visit and surgery. The ICD codes are set by the physician in charge of the patient and chosen for each hospital visit based on their clinical relevance. The registry includes records both from public and private hospitals, and also outpatient surgeries from 1994 onward. The index day was the discharge day of the first hospital visit. The cohort formation,

Key message

Risk of breast cancer is increased in women less than 40 years of age with surgically verified endometriosis.

its description and the quality assessment have been published previously.¹⁹

Information on the incident histologically verified carcinoma in situ and breast cancers in the endometriosis cohort were assessed by linkage to the Finnish Cancer Registry using the personal identity codes, which are available for all permanent residents in Finland. This registry includes information on the date of carcinoma in situ and cancer diagnosis, and topography and morphology of all malignancies diagnosed in Finland since 1953 allowing also analyses by histology and stage of the disease.²⁰ The breast tumor hormone receptor status is not registered. The follow up started on the index day and ended on the day of emigration, death or 4 December 2014, whichever came first. The data on emigrations and deaths were retrieved from the Finnish Population Register Center.

The endometriosis cohort consisted of 49 933 women who were assigned to sub-cohorts of ovarian ($n = 23\ 210$), peritoneal ($n = 20\ 187$), deep infiltrating ($n = 2372$), mixed ($n = 1120$) and "other/unknown" endometriosis ($n = 3044$) according to the site of endometriosis using the diagnostic codes from ICD versions 9 and 10 assigned at the index procedure (Supporting Information Table S1). First, the categories of ovarian and deep infiltrating endometriosis were retrieved. The combination of both ovarian and deep infiltrating endometriosis formed the sub-cohort of mixed endometriosis. Secondly, the category of peritoneal endometriosis was selected. Thirdly, those not stratified into the previous four categories formed the sub-cohort of "other/unknown" endometriosis. The categories of ovarian, deep infiltrating and mixed endometriosis could also include additional diagnoses of peritoneal endometriosis and other/unknown endometriosis. The sub-cohort of peritoneal endometriosis could also include additional diagnoses of other/unknown endometriosis but not ovarian, deep infiltrating or mixed endometriosis.¹⁹ Cases with adenomyosis as the only diagnosis were excluded, as histological data to confirm the diagnoses were not available. We focused on the three main sub-cohorts, namely: ovarian, peritoneal and deep infiltrating endometriosis.

2.1 | Statistical analyses

Women were divided to age groups by 10-year intervals (20-29, 30-39, 40-49, 50-59 and 60-69, ≥ 70). Person-years of follow up were calculated by 5-year age categories and calendar periods, and by time since the index day (<0.5, 0.5-4.9, 5-9.9 and ≥ 10 years). The expected number was defined by multiplying the accumulated person-years of follow up in each stratum by breast cancer incidence rate in the corresponding Finnish female population. The standardized incidence ratio (SIR) was calculated as the ratio

between the observed and the expected number of cancers. The 95% confidence intervals (95% CI) for the SIR were defined on the assumption that the number of observed cases followed a Poisson distribution. In the stratified analyses the same calculations were performed according to the histology (ductal/lobular/in situ carcinoma) and stage of the breast cancer (localized/non-localized) and presented according to age groups and time since index day.

2.2 | Ethical approval

We obtained approval from the ethics committee of the Hospital District of Helsinki and Uusimaa (238/13/03/03/2013) before initiation of this study. Permission from the National Institute for Health and Welfare (THL/546/5.05.00.2014) and the Population Register Centre (D1794/410/14) was also obtained for the register data and their linkages.

3 | RESULTS

Altogether there were 838 685 person-years of follow up during 1987-2014 with a mean follow-up time of 16.8 years. Six percent of the person-years accumulated in age categories under 30 years, 60% under 50 years and 14% over 60 years (Table 1). The sub-cohorts of ovarian and peritoneal endometriosis represented 89% of all person-years. The median age on the index day was 36.4 years.

The overall incidence of breast cancer was similar to that in the Finnish female population in the entire endometriosis cohort (1555 observed cases, SIR 0.99; 95% CI 0.94-1.03) and in all sub-cohorts of endometriosis (Table 2, Supporting Information Table S2). An increased risk of breast cancer was seen in the 20- to 29-year-olds (SIR 4.44; 95% CI 2.22-7.94, 11 cases), and in the 30- to 39-year-olds (SIR 1.28; 95% CI 1.03-1.57, 90 cases). Moreover, a slightly decreased risk of breast cancer was observed among the 50- to 59-year-olds (SIR 0.92; 95% CI 0.85-0.99) (Table 2).

Eleven women with endometriosis were diagnosed with breast cancer at less than 30 years (Table 3). The SIR of localized breast cancer in the 20- to 29-year-olds was 5.80 (95% CI 2.13-12.6; n =

6 cases), whereas that of non-localized disease was 3.15 (95% CI 0.86-8.07; n = 4 cases). The corresponding numbers among the 30- to 39-year-olds were 1.50 (95% CI 1.09-2.02; 43 cases) and 1.12 (95% CI 0.81-1.51; 42 cases).

In the stratified analyses the SIR of the breast cancer diagnosis increased 0.5-4.9 years after the endometriosis diagnosis in the whole cohort (SIR 1.15; 95% CI 1.01-1.29), especially in the sub-cohort of peritoneal endometriosis (SIR 1.30; 95% CI 1.06-1.56) (Table 2).

The SIR for ductal histology was 0.97 (0.91-1.02) and for lobular histology 0.99 (0.87-1.11). However, the SIR for ductal histology was increased in the 20- to 29-years-olds (SIR 4.17; 95% CI 1.91-7.92, 9 cases). The overall incidence of in situ carcinoma of the breast (n = 170) was increased in women with endometriosis (SIR 1.25; 95% CI 1.07-1.44). The risk of in situ carcinoma was highest in the age group of 50-59 years (SIR 1.35; 95% CI 1.08-1.66, 85 cases) (Table 2)

4 | DISCUSSION

We observed that women with surgically verified endometriosis do not have an overall increased risk of breast cancer. The risk did not differ according to the type of endometriosis either. The distribution of ductal and lobular histology of breast cancer did not differ from the reference population. However, we found an increased incidence of breast cancer among the 20- to 39-year-olds. The incidence of carcinoma in situ of the breast was increased.

The non-elevated overall incidence of breast cancer among women with endometriosis has been shown in several previous studies with different study designs and methods of ascertaining the diagnosis of endometriosis.¹⁰⁻¹⁴ A large British cohort study published in 2018 found no association between breast cancer and endometriosis among women receiving infertility treatment with assisted reproductive technologies.¹⁵ In contrast, an increased incidence of breast cancer has been observed in a recent study with histologically proven endometriosis.⁹

The differences in the overall incidence of breast cancer between different subtypes of endometriosis were small in our study. In two previous Nordic studies, the risk of breast cancer has also been assessed

TABLE 1 Number of women with surgically verified endometriosis by age in the beginning of the follow up, and numbers of person-years by dynamic age at follow up

Age (years)	Number of women at endometriosis diagnosis	Person-years, by years since endometriosis diagnosis				Whole follow up
		<0.5	0.5-4.9	5-9.9	≥10	
10-19	525	228	440	8	0	676
20-29	12 685	6135	35 577	9048	452	51 212
30-39	18 027	9027	79 485	66 145	31 458	186 115
40-49	15 286	7766	75 103	77 531	102 746	263 145
50-59	2985	1580	25 218	53 628	140 137	220 562
60-69	339	178	2392	7125	90 754	100 449
≥70	86	45	564	1067	14 850	16 526
Total	49 933	24 959	218 780	214 550	380 397	838 685

TABLE 2 Breast cancers and carcinoma in situ lesions of the breast among women with endometriosis, by time since endometriosis diagnosis and by dynamic age at follow up: observed number of cases (O), standardized incidence ratios (SIR) and 95% confidence interval (CI)

Dynamic age at follow up (years)		Time since endometriosis diagnosis														
		<0.5 year			0.5-4.9 years			5.0-9.9 years			≥10 years			Total		
		O	SIR	95% CI	O	SIR	95% CI	O	SIR	95% CI	O	SIR	95% CI	O	SIR	95% CI
Breast cancer																
20-29	0	0.00	0.00-14.5	7	4.18	1.68-8.60	4	7.69	2.10-19.7	0	0.00	0.00-130	11	4.44	2.22-7.94	
30-39	2	0.64	0.08-2.30	37	1.33	0.93-1.82	36	1.43	1.00-1.97	15	1.08	0.61-1.78	90	1.28	1.03-1.57	
40-49	11	1.00	0.50-1.79	114	1.01	0.83-1.20	112	0.91	0.75-1.08	194	1.16	1.01-1.33	431	1.04	0.95-1.14	
50-59	4	0.98	0.27-2.51	80	1.19	0.95-1.48	116	0.77	0.64-0.92	389	0.93	0.84-1.02	589	0.92	0.85-0.99	
60-69	0	0.00	0.00-7.07	13	1.74	0.92-2.96	23	0.94	0.60-1.41	350	0.97	0.87-1.07	386	0.98	0.89-1.08	
≥70	0	0.00	0.00-28.4	0	0.00	0.00-2.22	2	0.61	0.10-2.02	46	0.89	0.65-1.19	48	0.86	0.63-1.14	
Total	17	0.89	0.52-1.42	251	1.15	1.01-1.29	293	0.90	0.80-1.00	994	0.98	0.92-1.04	1555	0.99	0.94-1.03	
Carcinoma in situ																
20-29	0	0.00	0.00-331	0	0.00	0.00-52.8	0	0.00	0.00-180	0	0.00	0.00-4155	0	0.00	0.00-36.0	
30-39	0	0.00	0.00-29.5	3	2.53	0.52-7.40	0	0.00	0.00-3.19	0	0.00	0.00-5.22	3	0.95	0.20-2.76	
40-49	1	1.66	0.04-9.26	4	0.59	0.16-1.50	13	1.60	0.85-2.73	22	1.67	1.05-2.52	40	1.39	1.00-1.89	
50-59	0	0.00	0.00-11.1	9	1.55	0.71-2.94	23	1.64	1.04-2.46	53	1.23	0.92-1.61	85	1.35	1.08-1.66	
60-69	0	0.00	0.00-105	0	0.00	0.00-6.69	1	0.49	0.01-2.73	37	1.06	0.75-1.46	38	1.01	0.72-1.39	
≥70	0	0.00	0.00-787	1	14.3	0.36-79.6	0	0.00	0.00-24.6	3	0.96	0.20-2.81	4	1.19	0.33-3.06	
Total	1	0.90	0.02-5.02	17	1.18	0.68-1.88	37	1.45	1.02-2.00	115	1.21	1.00-1.44	170	1.25	1.07-1.44	

No cases of breast cancer or carcinoma in situ of the breast were found in the age group of 10-19 years (observed 0, expected <0.005).

TABLE 3 Details of women with endometriosis and subsequent breast cancer diagnosed under the age of 30 years

Type of endometriosis	Breast cancer					Follow up after breast cancer diagnosis	
	Latency ^a	Age ^b	Grade	Type	TNM	Recurrence (when ^c)	Total follow up ^e
Ovarian	2.4	26.7	II	Ductal	T1N0M0	Yes (12.0)	24.9
Ovarian	5.6	28.6	II	Ductal	T1N1MX	Yes (2.2)	4.3
Ovarian	5.7	28.9	III	Ductal	T1N0MX	No	4.8
Peritoneal	0.7	28.2	III	Ductal	T1N1M0	No	1.9
Peritoneal	1.8	26.8	N/A	N/A	N/A	N/A	11.3
Peritoneal	4.8	29.0	III	Ductal	T1N1M0	No	8.4
Deep	3.4	27.9	III	Ductal	T1N0M0	No	12.7
Deep	7.4	29.0	III	Ductal	T1N0M0	No	2.9
Other	1.1	28.1	N/A	Ductal	T1N0M0	Yes (2.7) ^d	4.9
Other	1.5	27.6	III	Ductal	T3N1M0	No	15.2
Other	5.9	28.7	II	Cribriform	T1N0MX	No	1.5

N/A, Not available.

^aYears between endometriosis diagnosis and breast cancer diagnosis.

^bAge at breast cancer diagnosis (years).

^cRecurrence (yes/no) during the follow up and the time of possible recurrence.

^dThis person also died due to breast cancer 4.9 years after breast cancer diagnosis.

^eFollow up from breast cancer diagnosis until death or 31 December 2014 (years).

in relation to the site of endometriosis (ovarian, pelvic, uterine and other endometriosis).^{7,11} The Swedish study found an increased risk of breast cancer with pelvic (SIR 1.8; 95% CI 1.2-2.6) and uterine endometriosis (SIR 1.4; 95% CI 1.1-1.7) but not with ovarian endometriosis.⁷ The Danish study did not find altered risks of breast cancer in association with any of the different locations of endometriosis.¹¹

Contrary to our study, a recent register-based study from Denmark found an increased risk of breast cancer in women with first diagnosis of endometriosis at ≥ 50 years of age (SIR 1.27; 95% CI 1.12-1.42).¹³ Moreover, a previous partially overlapping Danish register-based study reported that the risk of breast cancer was decreased if the endometriosis diagnosis had been made at < 40 years of age but increased along with increasing age at the first endometriosis diagnosis.¹¹ A Swedish register-based study found an increased risk of breast cancer (SIR 1.28; 95% CI 1.13-1.45) when endometriosis had been diagnosed between 50 and 60 years of age.¹⁰ In contrast, a prospective study from the USA reported that the risk of breast cancer was not increased in premenopausal or postmenopausal women with endometriosis.¹⁴

Early onset breast cancer is rare and therefore the absolute excess risk based on our study is small: in the age group of 20- to 29-year-olds, the relative risk of 4.4 would translate into eight breast extra cancers among 10 000 women with endometriosis followed up for 5 years. In the age group of 30- to 39-year-olds, the corresponding number would be five.

The reasons for the increased risk of breast cancer among young women with surgically diagnosed endometriosis are uncertain. Similar risk factors for both endometriosis and young-age

breast cancer might in part explain our finding. The known risk factors of early onset breast cancer, such as family history and known genetic predisposition, explain only approximately 10% of young-age breast cancer cases.²¹ However, we speculate that genetic factors predisposing to breast cancer might be more frequent among women with endometriosis at an early age. Other possible risk factors for breast cancer in young women include low body mass index and use of oral contraceptives.²¹ The women operated for endometriosis at a young age are also likely to be highly symptomatic, and therapies used in addition to surgery for symptom control, such as hormonal treatments and analgesics, might differently affect the risk of breast cancer in these women compared with older women with fewer symptoms.^{22,23} Recent meta-analyses indicated a slightly increased risk of breast cancer associated with current or recent use of hormonal contraceptives (risk ratio for current users 1.3; 95% CI 1.1-1.5, and for ever-users SIR 1.1; 95% CI 1.0-1.2)^{24,25} The use of progestin-only contraceptives has also been linked with breast cancer.^{26,27} In Finland, oral contraceptives and progestins are widely used in the treatment of endometriosis. In our study, data on hormonal therapies were not available and therefore the effect of hormonal therapies could not be estimated. According to the above-mentioned facts, we speculate that in our study, the SIRs might have been lower if we could have adjusted for hormonal therapies.

Breast cancer occurring at a young age is known to be aggressive and commonly diagnosed at a non-localized stage.²¹ However, the proportion of non-localized stage young-age breast cancer in our data was lower than in the breast cancer patients of similar

age in the reference population, as indicated by the higher SIR for a localized than for a non-localized stage of the breast cancer. We speculate that endometriosis patients visit their doctors and are examined more often, and therefore breast cancers of young women with endometriosis are diagnosed earlier than in the reference population.

The risk of breast cancer was slightly decreased among 50- to 59-year-old women with endometriosis (0.9-fold, 95% CI 0.9-1.0). On the other hand, the SIR of in situ cancers was increased in the age group of 40- to 59-year-olds. Endometriosis patients at 40 years of age or older might receive breast imaging examinations more frequently than the average female population. This may lead to increased detection of in situ cancers and their timely treatment, resulting in decreased risk of breast cancer.

The strength of our study is in the high accuracy of the registers.^{20,28} The cohort data from the Finnish Hospital Discharge Registry, cancer data from the Finnish Cancer Registry and the data on deaths and emigrations from the Finnish Population Register Centre were reliably linked using the unique personal identity codes available in all registries. Additional strengths of the study are the 27-year-long study period with almost 840 000 person-years and more than 1500 breast cancer cases. The large cohort size and the surgically verified diagnoses of endometriosis enabled us to assess the breast cancer risks for various subtypes of endometriosis. Still, the sub-cohort of deep infiltrating endometriosis is too small for reliable conclusions; deep infiltrating endometriosis is rare, and the definition of the disease entity was established only in the 1990s. Furthermore, our follow up does not properly extend into the oldest age groups—there were only 48 breast cancer cases in age groups of 70 years or more—and therefore our results on breast cancer risk in old age remain uninformative.

A limitation of this study is the lack of possibility to adjust the results for important potential confounding factors that might bias the SIRs of our study. The decreased parity or late onset of first pregnancy among women with endometriosis could increase the risk of breast cancer. The body mass index is decreased in women with endometriosis, which might lead to an increased incidence of breast cancer in premenopausal and a decreased incidence of breast cancer in postmenopausal women.^{29,30} Furthermore, data on hormonal therapies, a cause of possible bias in the study, were unavailable. We speculate that hormone replacement therapy is likely to be used less often due to the risk of endometriosis recurrence and therefore postmenopausal women with endometriosis might have decreased risk of breast cancer.

5 | CONCLUSION

The overall incidence of breast cancer was not increased in women with surgically verified endometriosis, nor was the risk increased in any of the specific types of endometriosis. The increased incidence of breast cancer in young women with endometriosis warrants further studies.

CONFLICT OF INTEREST

None of the authors reports conflicting interest, financial or otherwise, in relation to the present work.

ORCID

Liisu Saavalainen  <https://orcid.org/0000-0001-8002-0789>

Oskari Heikinheimo  <https://orcid.org/0000-0002-8671-130X>

REFERENCES

1. Eskenazi B, Warner ML. Epidemiology of endometriosis. *Obstet Gynecol Clin North Am.* 1997;24:235-258.
2. Bulun SE. Mechanisms of disease endometriosis. *N Engl J Med.* 2009;360:268-279.
3. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. *Fertil Steril.* 2012;98:511-519.
4. Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. *Fertil Steril.* 1997;68:585-596.
5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. *CA Cancer J Clin.* 2015;65:87-108.
6. Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction. *J Natl Compr Canc Netw.* 2010;8:1112-1146.
7. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. *Am J Obstet Gynecol.* 1997;176:572-579.
8. Surrey ES, Soliman AM, Johnson SJ, Davis M, Castelli-Haley J, Snabes MC. Risk of developing comorbidities among women with endometriosis: a retrospective matched cohort study. *J Womens Health.* 2018;27:1114-1123.
9. Saraswat L, Ayasina D, Cooper KG, Bhattacharya S, Horne AW. Impact of endometriosis on risk of further gynaecological surgery and cancer: a national cohort study. *BJOG.* 2018;125:64-72.
10. Melin A, Sparen P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. *Hum Reprod.* 2006;21:1237-1242.
11. Bertelsen L, Mellekjær L, Frederiksen K, Kjaer SK, Brinton LA, Sakoda LC, et al. Risk for breast cancer among women with endometriosis. *Int J Cancer.* 2007;120:1372-1375.
12. Kok VC, Tsai H-J, Su C-F, Lee C-K. The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly diagnosed endometriosis or adenomyosis: a population-based study. *Int J Gynecol Cancer.* 2015;25:968-976.
13. Mogensen JB, Kjær SK, Mellekjær L, Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. *Gynecol Oncol.* 2016;143:87-92.
14. Farland LV, Tamimi RM, Eliassen AH, et al. Laparoscopically confirmed endometriosis and breast cancer in the Nurses' Health Study II. *Obstet Gynecol.* 2016;128:1025-1031.
15. Williams CL, Jones ME, Swerdlow AJ, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. *BMJ.* 2018;362:k2644.
16. Gemmill JAL, Stratton P, Cleary SD, Ballweg ML, Sinaii N. Cancers, infections, and endocrine diseases in women with endometriosis. *Fertil Steril.* 2010;94:1627-1631.
17. Saavalainen L, Lassus H, But A, et al. Risk of gynecologic cancer according to the type of endometriosis. *Obstet Gynecol.* 2018;131:1095-1102.

18. Saavalainen L, Lassus H, But A, et al. A nationwide cohort study on the risk of non-gynecological cancers in women with surgically verified endometriosis. *Int J Cancer*. 2018;143:2725-2731.
19. Saavalainen L, Tikka T, But A, et al. Trends in the incidence rate, type and treatment of surgically verified endometriosis—a nationwide cohort study. *Acta Obstet Gynecol Scand*. 2018;97:59-67.
20. Pukkala E, Engholm G, Schmidt LKH, et al. Nordic Cancer Registries—an overview of their procedures and data comparability. *Acta Oncol*. 2018;57:440-455.
21. Narod SA. Breast cancer in young women. *Nat Rev Clin Oncol*. 2012;9:460-470.
22. Cata JP, Guerra CE, Chang GJ, Gottumukkala V, Joshi GP. Non-steroidal anti-inflammatory drugs in the oncological surgical population: beneficial or harmful? A systematic review of the literature. *Br J Anaesth*. 2017;119:750-764.
23. Cairat M, Fournier A, Murphy N, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk in a European prospective cohort study. *Int J Cancer*. 2018;143:1688-1695.
24. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. *Ann Intern Med*. 2012;156:635-648.
25. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. *Cancer Epidemiol Biomarkers Prev*. 2013;22:1931-1943.
26. Busund M, Bugge NS, Braaten T, Waaseth M, Rylander C, Lund E. Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: the Norwegian Women and Cancer Study. *Int J Cancer*. 2018;142:2293-2302.
27. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med*. 2017;377:2228-2239.
28. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. *Scand J Public Health*. 2012;40:505-515.
29. Peterson CM, Johnstone EB, Hammoud AO, et al. Risk factors associated with endometriosis: importance of study population for characterizing disease in the ENDO Study. *Am J Obstet Gynecol*. 2013;208:451.e1-451.e11.
30. Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. *Breast*. 2004;13:85-92.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Saavalainen L, Lassus H, But A, et al. A cohort study of 49 933 women with surgically verified endometriosis: Increased incidence of breast cancer below the age of 40. *Acta Obstet Gynecol Scand*. 2019;00:1-7. <https://doi.org/10.1111/aogs.13609>